Januarine 25 mg (Sitagliptin Hydrochloride Hydrate)

Adult dose

In monotherapy or combination therapy, this medication is administered once daily at a dose of 100 mg, with a maximum daily dose of 100 mg. It can be taken regardless of meals. For patients with renal impairment, dosage adjustments are necessary based on glomerular filtration rate. - Mild to moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2): No dosage adjustment needed. - Moderate renal impairment (eGFR ≥ 30 and < 45 mL/min/1.73 m2):

This medication may cause severe allergic reactions, so if symptoms such as skin rash, difficulty breathing, swelling of the face or lips occur within 3 months of the initial dose, use should be discontinued immediately, and a doctor should be consulted. As there have been reports of severe side effects causing inflammation of the pancreas, known as acute pancreatitis, if symptoms such as abdominal pain, nausea, or vomiting arise during treatment, immediate medical attention should be sought. Patients diagnosed with type 1 diabetes, diabetic ketoacidosis, or those who have a hypersensitivity to this medication or its components should not take this medication. Patients with reduced kidney function need to adjust the dosage of this medication, so renal function tests should be performed, and it should be taken as directed by a physician. During treatment, symptoms resembling a cold, headaches, indigestion, diarrhea, etc., may occur; if symptoms are severe, patients should inform their doctor. When taken with other hypoglycemic agents, especially insulin or sulfonylureas, there may be an increased risk of hypoglycemia, so blood sugar levels should be regularly monitored, and dosage adjustments should be discussed with a physician if necessary. While taking this medication, symptoms such as joint pain or the formation of blisters on the skin may occur. If these symptoms arise, notify a doctor immediately and discontinue use if necessary. Pregnant or lactating women are advised not to take this medication, and safety and efficacy have not been established for children and adolescents under 18 years of age. Elderly patients may have impaired kidney function, so assessment of kidney function before taking this medication is required, and regular monitoring is necessary. In case of overdose, measures should be taken to remove the drug from the gastrointestinal tract, clinical monitoring, including an electrocardiogram, should be conducted, and hemodialysis may be considered if necessary. This medication has relatively few drug interactions, but caution should be taken when using digoxin concurrently.

Serious side effects

• Urticaria
• severe swelling (angioedema)
• anaphylaxis
• rash
• Stevens-Johnson syndrome
• exfoliative skin disease
• acute pancreatitis
• severe hypoglycemia
• acute renal failure
• severe and disabling joint pain

Mild side effects

• Upper respiratory infection
• nasopharyngitis
• headache
• abdominal pain
• nausea
• diarrhea
• constipation
• vomiting
• muscle pain
• limb pain

This medication should be stored in a tightly closed container to prevent air from entering, and it is safest to store it at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the efficacy of the medication and prevents deterioration.

Appearance

Pink, round, biconvex, film-coated tablet

Package unit

28 tablets (14 tablets/PTPX2), 30 tablets (10 tablets/PTPX3)